Bristol Myers Squibb Co (BMY), Momenta Pharmaceuticals, Inc. (MNTA): White Collar Criminals Love Biotech Stocks
It's understandably very tempting for people with inside information to trade biotech stocks.
Posts Tagged ‘NYSE:BMY’
Intuitive Surgical, Inc. (ISRG), MAKO Surgical Corp. (MAKO): This Is the Leading Cause of Preventable Hospital Patient Deaths
When we go to the hospital, the last thing on our mind is that something could go wrong or that we could actually become sicker than when we first went in.
ImmunoGen, Inc. (IMGN), Seattle Genetics, Inc. (SGEN), Celldex Therapeutics, Inc. (CLDX): A Trio of Cancer Immunotherapy Innovators
The cancer world has been abuzz after an exciting ASCO conference. Bristol Myers Squibb Co.
Amgen, Inc. (AMGN), Bristol Myers Squibb Co. (BMY): Ovarian Cancer Drug Half Way There
The biotech giant announced today that its cancer drug trebananib combined with chemotherapy paclitaxel extended median progression-free survival in recurrent ovarian cancer patients...
Why The Pfizer Inc. (PFE)-Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Settlement Affects the Whole Industy
Generic-drug makers are always on the hunt for the next branded drug to take down.
Is Pfizer Inc. (PFE) a Buy?
The biggest pharmaceutical companies in the United States are in an enviable position. They sell products that are literally a matter of life and death.
Dendreon Corporation (DNDN), Celldex Therapeutics, Inc. (CLDX): A Promising Platform for Cancer Immunotherapy
A 2011 Nobel Prize in Physiology and Medicine is certainly impressive. Using a novel cancer treatment on yourself is both impressive and courageous. Dr.
GlaxoSmithKline plc (ADR) (GSK), Merck & Co., Inc. (MRK): Why You Should Care About This Diabetes Drug Saga
GlaxoSmithKline plc (ADR) (NYSE:GSK)'s diabetes drug Avandia causes heart issues. Or maybe it doesn't.
Should You Buy AstraZeneca plc (ADR) (AZN)?
Is AstraZeneca plc (ADR) (NYSE:AZN) a healthy stock for your portfolio? Investors who are in the know are getting more bullish.
Google Inc (GOOG), Eli Lilly & Co. (LLY) and More: Billionaire Jim Simons’ Buy Ups
Billionaire Jim Simons founded Renaissance Technologies ("RenTech"), his private investment firm, in 1982.
Revlimid Gains, Celgene Corporation (CELG) Loses
Celgene Corporation (NASDAQ:CELG) announced good news today about its blockbuster drug Revlimid. Did the stock jump as a result? Nope. Shares actually fell by more than 4%.
Merck & Co., Inc. (MRK), Clovis Oncology Inc (CLVS), Regulus Therapeutics Inc (RGLS): 3 Stocks to Get on Your Watchlist
I follow quite a lot of companies, so the usefulness of a watchlist to me cannot be overstated.
Intel Corporation (INTC), Bristol Myers Squibb Co. (BMY): Three Noteworthy Upgrades Worth a Look
Intel Corporation (NASDAQ:INTC) traded higher after last weekend’s feature story in Barron’s.
Bristol Myers Squibb Co. (BMY): This Pharma Is Trading Like a Biotech
This chart is just unbelievable.
Merck & Co., Inc. (MRK), Bristol Myers Squibb Co. (BMY): Breakthrough Melanoma Data Drives Pharmas Higher
Yesterday, Merck & Co., Inc. (NYSE:MRK) reported overwhelmingly positive interim results for its experimental melanoma drug lambrolizumab.
AstraZeneca plc (ADR) (AZN): This Pharma Company Is Making the Right Moves
Mergers and acquisitions appear to be continuously reshaping the pharmaceuticals industry.
Bristol Myers Squibb Co. (BMY), Ariad Pharmaceuticals, Inc. (ARIA): ASCO Investment Ideas
The American Society of Clinical Oncology annual meeting kicks off today.
Hedge Funds Are Selling GlaxoSmithKline plc (ADR) (GSK)
If you'd ask most stock holders, hedge funds are assumed to be underperforming, outdated financial vehicles of yesteryear.
AbbVie Inc (ABBV): Hedge Funds and Insiders Are Bullish, What Should You Do?
According to most market participants, hedge funds are assumed to be underperforming, old financial vehicles of yesteryear.
Three Things About to Move Johnson & Johnson (JNJ) Stock
Johnson & Johnson (NYSE:JNJ) may be involved in everything from hip implants to pharmaceuticals, but it's the latter that brings in the majority of the profits and fuels any...
Hedge Funds Are Dumping GlaxoSmithKline plc (ADR) (GSK)
GlaxoSmithKline plc (ADR) (NYSE:GSK) was in 18 hedge funds' portfolio at the end of March. GSK investors should be aware of a decrease in enthusiasm from smart money lately.
VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA): This Obesity Drugmaker Is Badly In Need of a Marketing Partner
As recently as a decade ago, the biggest hurdle for biotech companies wasn't competition from their peers or even the sale price of their drugs.
Bristol Myers Squibb Co. (BMY), Gilead Sciences, Inc. (GILD), Halozyme Therapeutics, Inc. (HALO): 3 Stocks to Watch Ahead of ASCO
At the annual ASCO meeting in Chicago, thousands of health-care researchers and professionals unite to advance cancer treatment.
Dendreon Corporation (DNDN), Bristol Myers Squibb Co. (BMY): Why Immunotherapy Stocks Could Be Set for a Big Move
If the JPMorgan Healthcare Conference in January is the mecca of all health-care events during the year, then the American Society of Clinical Oncology's annual meeting in Chicago...
VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA): The Top Three Causes of Diabetes
A whopping 25.3 million people in the U.S. right now are diabetic, with an additional 79 million Americans in the pre-diabetes stage.
This Metric Says You Are Smart to Sell Bristol Myers Squibb Co. (BMY)
Bristol Myers Squibb Co. (NYSE:BMY) was in 33 hedge funds' portfolio at the end of the first quarter of 2013.
Amgen, Inc. (AMGN), Bristol Myers Squibb Co. (BMY): Can Financial Innovation Unlock a Cure for Cancer?
A few years ago, Andrew W. Lo from the MIT Sloan School of Management gave a lengthy talk at a meet-and-greet for prospective students of the Master of Finance program.
Pfizer Inc. (PFE), AstraZeneca plc (ADR) (AZN): The Top Three Diseases Caused by Stress
Let's face it; we all dislike stress, but it's something we all live with to some degree.
Merck & Co., Inc. (MRK), Pfizer Inc. (PFE), AstraZeneca plc (ADR) (AZN) – Pick Your Poison: Overweight or High Cholesterol
Overweight and have high cholesterol? You may have to pick one to work on at a time, according to data from the lab of John Thyfault, an associate professor of nutrition and exercise...
Bristol Myers Squibb Co. (BMY), Pharmacyclics, Inc. (PCYC): Hedging Against Leukemia
As I noted 11 weeks ago, cancer statistics are both staggering and disappointing.
MannKind Corporation (MNKD): Why Have Shares Moved?
MannKind Corporation (NASDAQ:MNKD) took one giant leap over the past few days.
Roche Holding Ltd. (ADR) (RHHBY), Bristol Myers Squibb Co. (BMY): Cancer Meeting Highlights the Good and Bad of the Immune System
Biotech investors rejoice. The ASCO abstracts are here.
Verizon Communications Inc. (VZ), General Mills, Inc. (GIS) & 4 Must-Own Stocks
As the chatter surrounding a market pullback continues to build, these companies remain good investments. We look at fours stocks in four different sectors that meet the below...
And The Best Bargain Is…Bristol Myers Squibb Co. (BMY), Eli Lilly & Co. (LLY) or Pfizer Inc. (PFE)?
Many stocks within the pharmaceutical industry have rallied significantly over the past few years and now sit at multi-year highs.
Busy Day For Bristol Myers Squibb Co. (BMY) Options As Shares Sprint Higher
Bristol Myers Squibb Co. (NYSE:BMY) – Shares in drug maker, Bristol Myers Squibb Co.
Is Gilead Sciences, Inc. (GILD) Still A Buy?
Gilead Sciences, Inc. (NASDAQ:GILD) reported a relatively rare earnings miss in the first quarter on May 2.
Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK) & What To Watch
Pharmaceutical companies in the U.S. are not having it easy these days.
Pfizer Inc. (PFE), Merck & Co., Inc. (MRK): Buying the Pharma Dips
Pfizer Inc. (NYSE:PFE) saw a strong pullback earlier this month, with its stock tumbling over 6% after reporting first-quarter earnings results.
Onyx Pharmaceuticals, Inc. (ONXX), Pfizer Inc. (PFE), And Kidney Cancer’s Top Bets
As I noted nine weeks ago, cancer statistics are both staggering and disappointing.
Bristol Myers Squibb Co. (NBMY), Eli Lilly & Co. (LLY), Johnson & Johnson (JNJ): Six Big Pharma Stocks With Lower Credit Risk Than U.S. Treasuries: Part I
The healthcare sector has been known for paying dependable dividends and producing strong total returns over time.
Bristol Myers Squibb Co. (BMY), And Talk Of Dividend Yields In Pharma
As the market continues to climb, investors are beginning to see thinning dividend yields on many of their big pharma shares.
Merck & Co., Inc. (MRK): Post-Earnings Performance Questions
Merck & Co., Inc. (NYSE:MRK) stock could move up or down this week after the pharmaceutical company reports earnings on Wednesday.
How Will Merck & Co., Inc. (MRK)’s Earnings Fare Tomorrow?
Tomorrow, Merck & Co., Inc. (NYSE:MRK) will release its latest quarterly results.
Merck & Co., Inc. (MRK), Pfizer Inc. (PFE), AstraZeneca plc (ADR) (AZN), Bristol Myers Squibb Co. (BMY): A New Diabetes Duo Emerges
That's the message from today's announcement that Pfizer Inc. (NYSE:PFE) is out-licensing its diabetes drug candidate ertugliflozin to Merck & Co., Inc. (NYSE:MRK).
Merck & Co., Inc. (MRK): How This Can Eventually Lead To Healthy Returns
In the big pharma sector, it can oftentimes be hit or miss when seeking the next big growth stock.
Apple Inc. (AAPL), Novo Nordisk A/S (ADR) (NVO) & ‘The Most Sustainable Company in the World’
In January of 2012, Business Magazine released a list of the most sustainable companies in the world. You might be surprised to see who topped their list.
Pfizer Inc. (PFE), Bristol Myers Squibb Co. (BMY), and Alzheimer’s Milkshakes: The Growth of Medical Nutrition
A milkshake is not foremost on most people’s list of treatments for the neurological disorder Alzheimer’s.
Pfizer Inc. (PFE), Merck & Co., Inc. (MRK) & More: Drug Stocks on Citi’s Dividend Buy List
Barron's recently posted Citi's updated list of large, financially strong, high-yielding, dividend-paying companies.
Bristol Myers Squibb Co. (BMY): Growing Bigger and Better
Bristol Myers Squibb Co. (NYSE:BMY) has been in the spotlight for its so-called “desired” acquisitions and its size issues, along with patent expiration news.
